ECCMID

SCYNEXIS Reports First Quarter 2024 Financial Results and Provides Corporate Update

Retrieved on: 
星期三, 五月 8, 2024
Infection, Congress, Candida glabrata, Investment, Mouse, Data analysis, NIH, Fungal infection, Research, ECCMID, Clinical trial, FURI, GSK, Antimalarial medication, Patient, Candidiasis, CMC, Chemistry, National Institutes of Health, Candida auris, Biotechnology, Mucorales, Pharmaceutical industry

Phase I-enabling development activities for SCY-247, the second generation fungerp from SCYNEXIS’ proprietary antifungal platform, continue to progress.

Key Points: 
  • Phase I-enabling development activities for SCY-247, the second generation fungerp from SCYNEXIS’ proprietary antifungal platform, continue to progress.
  • Research and development expense for the quarter ended March 31, 2024 was $7.2 million compared to $6.8 million for the same period in 2023.
  • SG&A expense for the quarter ended March 31, 2024 decreased to $3.7 million from $4.8 million for the same period in 2023.
  • Cash, cash equivalents and investments totaled $94.2 million on March 31, 2024, compared to $98.0 million on December 31, 2023.

T2 Biosystems Announces First Quarter 2024 Financial Results

Retrieved on: 
星期一, 五月 6, 2024
FDA, ASPR, International, Research, ECCMID, U.S. FDA, ATM, Panel, Blood culture, CRG, Acinetobacter baumannii, Infection, Journal, Growth, Sepsis

LEXINGTON, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced unaudited financial and operational results for the first quarter ended March 31, 2024.

Key Points: 
  • LEXINGTON, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced unaudited financial and operational results for the first quarter ended March 31, 2024.
  • Advanced the T2Resistance Panel toward U.S. FDA 510(k) submission, expected to occur during the third quarter of 2024.
  • “Looking ahead, we plan to launch T2Lyme Panel and file the FDA submission for the T2Resistance Panel during the third quarter of 2024.
  • The Company raised $2.2 million in net proceeds through ATM sales in the first quarter of 2024.

MGI Showcases Life Science Excellence at ESCMID Global 2024 with Latest DNBSEQ-E25 Sequencer and New Partnership with ABL Diagnostics

Retrieved on: 
星期一, 四月 29, 2024
Infection, Congress, E25, Genomics, ABL, Laboratory, Health, ESCMID, Software, Business development, ECCMID, Partnership, Research, Workflow, NGS, DNA, DNB, Patient, Microbiology, MGI, Database, HIV, PFI, Exhibition, FASTQ, DNA sequencing, Tuberculosis

During the event taking place from 27-30 April in Barcelona, MGI and ABL Diagnostics (Woippy, France, Euronext: ABLD – ISIN: FR001400AHX6) are pleased to announce its partnership and the compatibility of ABL Diagnostics' DeepChek® assays with MGI's DNBSEQ™ platforms.

Key Points: 
  • During the event taking place from 27-30 April in Barcelona, MGI and ABL Diagnostics (Woippy, France, Euronext: ABLD – ISIN: FR001400AHX6) are pleased to announce its partnership and the compatibility of ABL Diagnostics' DeepChek® assays with MGI's DNBSEQ™ platforms.
  • "Once again, MGI showcases our commitment to supporting healthcare and scientific research and applications across Europe and Africa.
  • We at MGI believe that the power and potential of genomics are boundless," said Dr. Yong Hou, General Manager of MGI Europe and Africa.
  • Moreover, at this year's ESCMID Global 2024, MGI announced a technical assessment of solutions by ABL Diagnostics (ABL), a Euronext-listed company that develops molecular biology assays and software for microbiology genotyping.

Microbix Collaborator Introduces New Lab Accreditation Program

Retrieved on: 
星期四, 四月 25, 2024
RUO, Mycoplasma genitalium, EQA, Pelvic inflammatory disease, Infection, OTCQX, Woman, Infertility, Poster, Bacteria, MDX, AMR, ECCMID, TSX, STI, Accreditation, Vertically transmitted infection, Temperature, Drug resistance, Chronic pain, Non-gonococcal urethritis, Ectopic pregnancy, IVD

The poster is titled “Mycoplasma genitalium, Drug Resistance, Nucleic Acid Detection; Introducing a New External Quality Assessment Scheme” and was authored by scientists from both Labquality and Microbix.

Key Points: 
  • The poster is titled “Mycoplasma genitalium, Drug Resistance, Nucleic Acid Detection; Introducing a New External Quality Assessment Scheme” and was authored by scientists from both Labquality and Microbix.
  • The pilot EQA program confirmed the performance of these QAPs across all clinical labs, instrument platforms, and assays.
  • These Mgen QAPs are now available from Microbix as part of its PROCEEDx®FLOQ® (RUO) or REDx™FLOQ® (IVD) catalogue of products.
  • Purchase enquiries for these or other Microbix QAPs can be e-mailed to [email protected] .

QIAGEN expands tuberculosis portfolio with new NGS Panel to support real-time surveillance and combat antimicrobial resistance

Retrieved on: 
星期三, 四月 24, 2024
TST, Genetically modified bacteria, WHO, Virtual reality, CDC, Multidrug-resistant tuberculosis, Bacteria, AMR, ESCMID, QIAGEN, ECCMID, MDR-TB, WGS, Doctor of Philosophy, Research, Workflow, Sputum, NGS, PCR, Disease, Patient, Panel, Mycobacterium tuberculosis, QGEN, Gold, Infection, D20, Emerging, Tuberculosis, Cerebrospinal fluid, Vaccine

The QIAseq xHYB Mycobacterium tuberculosis Panel represents a major advancement in solving the problem of bacterial WGS from complex host samples, using next-generation sequencing (NGS).

Key Points: 
  • The QIAseq xHYB Mycobacterium tuberculosis Panel represents a major advancement in solving the problem of bacterial WGS from complex host samples, using next-generation sequencing (NGS).
  • By eliminating the need for a 4-to-6-week bacterial culture, the panel significantly accelerates the process of obtaining results.
  • “The introduction of the QIAseq xHYB Mycobacterium tuberculosis Panel reflects our ongoing commitment to address global health challenges like TB and antimicrobial resistance,” said Nitin Sood, Vice President, Head of the Life Sciences Business Area at QIAGEN.
  • The QIAseq xHYB Mycobacterium tuberculosis Panel also plays a vital role in the detection and management of antimicrobial resistance (AMR), a growing concern in TB treatment.

BiomX to Present Data from Phase 1b/2a Study of BX004 for the Treatment of Cystic Fibrosis Patients with Chronic Pulmonary Infections at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2024)

Retrieved on: 
星期二, 四月 23, 2024
NESS, Abstract, Cystic fibrosis, ECCMID, Patient

CAMBRIDGE, Mass.

Key Points: 
  • CAMBRIDGE, Mass.
  • and NESS ZIONA, Israel, April 23, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced the Company will present data from the Phase 1b/2a study of BX004 for the treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa pulmonary infections at ECCMID 2024, which is being held from 27-30 April 2024, in Barcelona, Spain.
  • The abstract submitted by the Company was selected as a “Top Poster”, ranking it among the 1-2% of top-rated abstracts in the category submitted and accepted at ECCMID 2024.
  • Chronic Pseudomonas aeruginosa pulmonary infection treated with a nebulised phage cocktail in patients with cystic fibrosis: a phase 1b/2a randomised, double-blind, placebo-controlled, multicentre study

Paratek Pharmaceuticals Presenting New Data from NUZYRA® (Omadacycline) and Investigator-Initiated Pre-Clinical Studies at European Society of Clinical Microbiology & Infectious Diseases Global (ESCMID Global) 2024

Retrieved on: 
星期四, 四月 18, 2024
Infection, University of Southern California, Medical microbiology, University, Mycobacteroides abscessus, Tuberculosis, Epidemiology, ESCMID, ECCMID, Erasmus MC, Urinary tract infection, Science, MAC, Antimycobacterial, Mycobacterium avium complex, Clinical pharmacy, Immunity, TB, National Jewish Health, Division, Pharmaceutical industry

BOSTON, April 18, 2024 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc., a biopharmaceutical company focused on providing innovative medical therapies that create positive patient stories in the hospital, community and public health settings, today announced that three new pre-clinical studies with NUZYRA® (omadacycline) will be presented at European Society of Clinical Microbiology & Infectious Diseases Global (ESCMID Global, formerly ECCMID).

Key Points: 
  • BOSTON, April 18, 2024 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc., a biopharmaceutical company focused on providing innovative medical therapies that create positive patient stories in the hospital, community and public health settings, today announced that three new pre-clinical studies with NUZYRA® (omadacycline) will be presented at European Society of Clinical Microbiology & Infectious Diseases Global (ESCMID Global, formerly ECCMID).
  • The hybrid conference will be held April 27-30 at the Fira Gran Via in Barcelona, Spain.
  • “Paratek continues to invest in science to further our understanding of NUZYRA, as well as explore its future utility in addressing additional unmet patient needs,” said Randy Brenner, chief development and regulatory officer of Paratek.
  • “Next week’s ESCMID presentations include a study assessing the potential immunomodulating properties of NUZYRA in addition to its antibacterial activity.

Longhorn Vaccines and Diagnostics Presents New Data on its Best-In-Class Infectious Disease Vaccine and Antibody Portfolio at ECCMID 2024

Retrieved on: 
星期六, 四月 27, 2024
Science, Other Science, Research, Pharmaceutical, General Health, Health, Infectious Diseases, Other Health, Infection, Immunoglobulin G, PGN, University, Public, Hook effect, Coronavirus, Mouse, Gram-positive bacteria, Risk, ECCMID, MTB, Vaccine, Human, GA4, Immunodeficiency, Mycobacterium tuberculosis, Virus, Pig, Immune system, Antibody, Tuberculosis, Bird

Longhorn Vaccines and Diagnostics , a One Health company developing vaccines and diagnostic tools for global public health and zoonosis concerns, presented positive data from three key studies of its infectious disease franchise at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2024.

Key Points: 
  • Longhorn Vaccines and Diagnostics , a One Health company developing vaccines and diagnostic tools for global public health and zoonosis concerns, presented positive data from three key studies of its infectious disease franchise at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2024.
  • ECCMID is taking place online and in-person in Barcelona, Spain from April 27-30, 2024.
  • Longhorn’s vaccine and antibody product candidates focus on rapidly mutating viruses that include influenza, coronavirus, and antimicrobial resistant pathogens.
  • “We are very excited to present the first data from our universal influenza vaccine in pigs,” said Jeff Fischer, President Longhorn Vaccines and Diagnostics.

ESCMID Global 2024: Shionogi presents real-world data demonstrating efficacy of Fetcroja® / Fetroja® (cefiderocol) in critically ill patients with certain difficult-to-treat bacterial infections

Retrieved on: 
星期四, 四月 18, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Stenotrophomonas maltophilia, Mortality, Genetically modified bacteria, Cefiderocol, Safety, Kidney disease, Infection, Survival, Immunosuppression, Diabetes, Pseudomonas aeruginosa, ECCMID, Head, Urinary tract infection, CHAI, Patient, Hospice and palliative medicine, Gram-negative bacteria, Klebsiella pneumoniae, Chronic obstructive pulmonary disease, Pharmaceutical industry

Please see below under About Cefiderocol for full indications of Fetroja in the U.S.

Key Points: 
  • Please see below under About Cefiderocol for full indications of Fetroja in the U.S.
  • Additionally,19.5% of patients had polymicrobial infections.1
    The study included 261 critically ill adult patients with limited treatment options who received cefiderocol for less than 28 days as part of Shionogi’s Early Access Program in Spain.
  • Real-world evidence is particularly important when reviewing antibiotic use for multidrug-resistant pathogens because of the challenges of conducting randomized clinical trials.
  • We also know how important it is to ensure equitable, global, access to essential medicines like cefiderocol.

Enanta Pharmaceuticals Announces Data Presentation at ESCMID Global 2024

Retrieved on: 
星期三, 四月 17, 2024
Health, Infectious Diseases, COVID-19, Clinical Trials, Pharmaceutical, Biotechnology, Safety, ESCMID, Political moderate, SPRINT, ECCMID, Medication, Virology, Pharmaceutical industry

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for indications in virology and immunology, today announced that data from the company’s SPRINT (SARS-Cov-2 PRotease INhibitor Treatment) study of EDP-235 has been accepted for a poster presentation at ESCMID Global 2024 (formerly ECCMID) being held April 27–30 in Barcelona, Spain.

Key Points: 
  • Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for indications in virology and immunology, today announced that data from the company’s SPRINT (SARS-Cov-2 PRotease INhibitor Treatment) study of EDP-235 has been accepted for a poster presentation at ESCMID Global 2024 (formerly ECCMID) being held April 27–30 in Barcelona, Spain.
  • The poster presentation includes primary and post-hoc analyses from the double-blind, placebo-controlled Phase 2 clinical trial of EDP-235, a 3CL protease inhibitor, in non-hospitalized, symptomatic adults with mild or moderate COVID-19 who were not at high risk for severe disease.
  • Poster Title: “Efficacy and Safety of EDP-235 in Non-Hospitalized Adults with Mild or Moderate COVID-19: Results from the Phase 2 SPRINT Study”